Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Endocrine resistant"'
Autor:
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-9 (2024)
Abstract Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways. The breast ER an
Externí odkaz:
https://doaj.org/article/fea4ab7d83664113b74a8251bd20c929
Autor:
Kai‐Ming Zhang, De‐Chang Zhao, Ze‐Yu Li, Yan Wang, Jian‐Nan Liu, Tian Du, Ling Zhou, Yu‐Hong Chen, Qi‐Chao Yu, Qing‐Shan Chen, Rui‐Zhao Cai, Zi‐Xuan Zhao, Jia‐Lu Shan, Bing‐Xin Hu, Hai‐Liang Zhang, Gong‐Kan Feng, Xiao‐Feng Zhu, Jun Tang, Rong Deng
Publikováno v:
Advanced Science, Vol 11, Iss 35, Pp n/a-n/a (2024)
Abstract Endocrine‐resistant ER+HER2– breast cancer (BC) is particularly aggressive and leads to poor clinical outcomes. Effective therapeutic strategies against endocrine‐resistant BC remain elusive. Here, analysis of the RNA‐sequencing data
Externí odkaz:
https://doaj.org/article/0bb97eb8b1b84525bea91c117811fad7
Publikováno v:
Acta Materia Medica, Vol 3, Iss 1, Pp 57-71 (2024)
Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor. However, the issue of drug resistance poses a significant clinical cha
Externí odkaz:
https://doaj.org/article/a720e144bdbd48b290ccb3685f9b95a3
Autor:
Yubo Wang, Jian Min, Xiangping Deng, Tian Feng, Hebing Hu, Xinyi Guo, Yan Cheng, Baohua Xie, Yu Yang, Chun-Chi Chen, Rey-Ting Guo, Chune Dong, Hai-Bing Zhou
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 12, Pp 4963-4982 (2023)
Endocrine-resistance remains a major challenge in estrogen receptor α positive (ERα+) breast cancer (BC) treatment and constitutively active somatic mutations in ERα are a common mechanism. There is an urgent need to develop novel drugs with new m
Externí odkaz:
https://doaj.org/article/f84e6d8203d24831bb9c9b09d3cda2b2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kang Wang, Lun Li, Sebastià Franch‐Expósito, Xin Le, Jun Tang, Qing Li, Qianxue Wu, Laia Bassaganyas, Jordi Camps, Xiang Zhang, Hongyuan Li, Theodoros Foukakis, Tingxiu Xiang, Jiong Wu, Guosheng Ren
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2413-2431 (2022)
Estrogen receptor‐positive and human epidermal growth factor receptor 2‐negative (ER+HER2−) breast cancer accounts for ~ 60–70% of all cases of invasive breast carcinoma. High‐grade ER+HER2− tumors respond poorly to endocrine therapy. In
Externí odkaz:
https://doaj.org/article/122cab742387465fa543be90dac2717e
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 2, Pp 240-251 (2022)
Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to rise, the rate of brain metastasis has also increase
Externí odkaz:
https://doaj.org/article/c7e479d562114d0b8081d0e751401a40
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Muriel Lainé, Sean W. Fanning, Ya-Fang Chang, Bradley Green, Marianne E. Greene, Barry Komm, Justyna D. Kurleto, Linda Phung, Geoffrey L. Greene
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents. Breast cance
Externí odkaz:
https://doaj.org/article/9662ade02114434d836902ed3ba109b6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.